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100% of patients with CMV viremia and no CMV gut disease
were lymphopenic. There did not appear to be any associa-
tion between CMV PCR copy number and absolute lympho-
cyte count (r¼0.016; p¼0.49). There was no apparent pattern
or relationship between CMV PCR copy number and degree
of cytopathic changes on intestinal biopsy.
Conclusion: We hypothesized that all patients with gut-
associated CMV disease would have corresponding CMV
viremia. One patient with biopsy-proven disease had nega-
tive CMV PCR, so we are evaluating for potential sources of
false positivity because gut-conﬁned CMV (CMV disease
without CMV viremia) is relatively uncommon in the HSCT
setting. Our data support that a lack of CMV viremia does not
rule out gut-associated CMV disease and that intestinal bi-
opsy by EGD or colonoscopy is warranted in this patient
population.389
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Patients with end stage renal disease (ESRD) historically have
not been offered allogeneic hematopoietic cell trans-
plantation (HCT) because of the presumed high risk of
toxicity. Use of nonmyeloablative (NMA) conditioning regi-
mens has made allogeneic HCT a viable option for patients
with variety of baseline medical comorbidities. We report
our experience with NMA allogeneic HCT for patients with
ESRD who were on hemodialysis (HD) or peritoneal (PD)
before receiving NMA allogeneic HCT. We reviewed our
institutional database at Fred Hutchinson Cancer Research
Center from 1997-2013. Eight patients were on dialysis (7 on
HD and 1 on PD) before they received NMA allogeneic HCT
(Age: 13-67; F/M: 3/5). Six of eight patients (75%) were on
dialysis when the decision for NMA allogeneic HCT was
made. One patient was started on HD before the conditioning
regimen and one required HD after ﬁnishing the condition-
ing and before the infusion of stem cells. Etiologies of ESRD
included: Myeloma kidney (3), polycystic kidney disease (2),
hemolytic uremic syndrome secondary to E-coli infection (1),
acute tubular necrosis (ATN) (1) and acute obstructive kidney
injury (AKI) (1). Four patients (50%) had previously received
an autologous transplant (as part of an auto/allo tandem
approach). Primary diagnosis included multiple myeloma
(n¼4), NHL (n¼2) MDS/MPN (n¼1), WiskotteAldrichTable
Results of treosulfan use in conditioning in children vs adults
Children




3y OS ALL-51%, AML-46%,
inherited disorders-80%, hemoglobinopath
Other 3y EFS ALL-39% AML-40%syndrome (n¼1). The conditioning regimen included Flu-
darabine/2GyTBI (n¼3), 2GyTBI (n¼1), Fludarabine/
Melphalan/2GyTBI (n¼1) and Fludarabine/Cyclophospha-
mide/2GyTBI (n¼1). Fludarabine and Melphalan were
administered after dialysis but with no dose reduction.
Immunosuppression included Mycophenolate mofetil with
cyclosporine (n¼5) or Tacrolimus (n¼3). Seven of eight pa-
tients died during the follow-up period (median 10.1; range
0.2-84.6 months). Two patients died within 2 weeks after
transplant and neither was on dialysis at the time of referral
for HCT. One had progressive Mantle cell lymphoma and was
started on HD 7 days before the HCT because of obstructive
AKI secondary to abdominal lymphadenopathy and the
second patient had a diagnosis of multiple myeloma and
required HD because of ATN after the conditioning regimen
before stem cell infusion. This patient died from multi-sys-
tem organ failure secondary to conditioning regimen-related
toxicities (Flu/Mel/TBI). All other 7 patients survived for a
median of 11.5 months (range 3.8 e 84.6). Causes of death
included: CMV pneumonia, fungal CNS infection, uncon-
trolled bleeding during open heart surgery, relapse, and
sepsis. One patient is still alive 3.8 months post auto/allo
HCT. In conclusion, review of these cases indicates that NMA
allogeneic SCT for patients with ESRD on dialysis at the time
of referral did not lead to adverse outcomes but initiation of
dialysis shortly before HCT was associated with early mor-
tality after transplant.390
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Objective: The published literature was reviewed to assess
the impact of treosulfan for conditioning before allogeneic or
autologous SCT to identify possible differences between
children and adults with respect to toxicity, acute or chronic
graft versus host disease (a/cGVHD), treatment related
mortality (TRM), overall survival (OS), disease free survival
(DFS).
Material and Methods: Pediatric (patients aged <18 years)
data originated from EBMT megaﬁle report (EBMT Annual
Meeting 2012) and 1 study of 28 patients from India. Adult
data originated from 34 studies from European countries
(Germany, Poland, Italy, France, Finland, Italy), Israel (4
studies, 119 patients) and USA (1 study, 60 patients). The
analysis was performed based on data published before
October, 1st, 2013. Pediatric data included 604 (521 allo + 83
auto) evaluable patients out of total 871 patients reported.Adults
) Gastro-intestinal II (up to 33%), III-IV (10-29%)
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Median 2y DFS 55% (range 35-82),
RI 25% (range 15-36), 100d TRM 11.8%.
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patients out of total 835 patients reported. In pediatric cohort
165 patients suffered from malignancies, 356 patients were
transplanted for non-malignant diseases; 437 underwent a
ﬁrst SCT, 87 had a subsequent transplant. In adult group 626
were treated for hematological malignancies and 18 for non-
malignant diseases (SAA or thalassemia). No data on auto-
SCT in adults were published after 2004. The majority of
pediatric patients received treosulfan in dose 39-45 mg/m2
(332 patients, 62%). Most of adult patients treated after 2007
received dose of 42 mg/m2.
Results: The main indications for treosulfan use in pediatric
population were non-malignant diseases (68%) or second
SCT, while among adults older age (>50 years) and/or
comorbidities disqualifying from myeloablative condition-
ing. No correlation between the given treosulfan dose and
the grade III/IV toxicity was observed both in children and in
adults. No association between dose and GVHD, OS, DFS,
relapse incidence and TRMwas found both in children and in
adults.
Conclusions: Treosulfan-based conditioning with its low
toxicity proﬁle and dose-dependent myelotoxicity is a good
option in children treated with non-malignant diseases.
Additionally, both children and adults not eligible for con-
ventional transplant regimen can be offered this treatment
with acceptable results. Toxicity and survival were similar in
children and adults, while acute and chronic GVHD incidence
were higher in adult population.391
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Donor-derived malignancy (DDM) is a rare but often fatal
complication of alloBMT, with a reported incidence of 0.1-5%.
AlloBMT utilizing high-dose post-transplantation cyclo-
phosphamide (PT/Cy) as GVHD prophylaxis produces excel-
lent rates of engraftment and low rates of acute and chronic
GVHD. Because exposing the allograft to cytotoxic chemo-
therapy may theoretically increase the risk of DDM, we
evaluated the incidence of DDM after alloBMT with PT/Cy.
From 2000-2012, 790 patients (median age 51y, range 1-74y)
received T-cell replete alloBMT with high-dose PT/Cy at
Johns Hopkins, including 313 (40%) who received PT/Cy as
sole GVHD prophylaxis. Of these transplants, 349 (44%) were
HLA-haploidentical and 346 (44%) were myeloablative. Me-
dian donor age was 41y (range 13-79y). With a median
follow-up of 3y (range, 0.8-9.4y) in patients without events,
the 3 year PFS and OS probabilities were 42% and 56%
respectively. Five cases (5/790¼0.6%) of DDMwere identiﬁedas well as one case of clonal, donor-derived LGL leukemia
that resolved without any therapy. By competing-risk anal-
ysis, the probability of DDM was 0.6% at 1 y, 0.8% at 5 y, and
2% overall (Figure). In the 5 identiﬁed cases of DDM, the
median patient age was 41y (range 18-65 y) at BMT and
median donor age was 41y (31-67y). These patients were
initially transplanted for ALL (1), NHL (3), or Hodgkin lym-
phoma (1). Two patients received myeloablative condition-
ing and 3 received additional GVHD prophylaxis with
mycophenolate mofetil and tacrolimus. The median time
from BMT to the diagnosis of DDMwas 1.3y (range 0.5-6.3y).
DDMs consisted ofMDS (1), AML (3), and CMML (1). All of the
patients received treatment for their DDM; 2 are long term
survivors and 3 died of their DDM. The incidence of devel-
oping a DDM after high-dose PT/Cy is rare, and is within the
range reported for other transplant platforms.392
Ex eVivo T Cell Depleted Allogeneic (TCD) Hematopoietic
Stem Cell Transplantation for Advanced Chronic
Myeloﬁbrosis: MSKCC Experience
Roni Tamari, Ann A. Jakubowski, Esperanza Papadopoulos,
Craig Sauter, Sergio A. Giralt, Hugo Castro-Malaspina.
Department of Medicine, Adult Bone Marrow Transplant
Service, Memorial Sloan-Kettering Cancer Center, New York, NY
Introduction: Allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) is the only potentially curative treat-
ment option for MF. The role of ex evivo TCD allo-HSCT
hasn’t been reported in patients with advanced MF.
Patients: Between 5/1990-4/2013, 12 pts underwent TCD
transplant at MSKCC for MF; 9 had primary MF, 2 post ET and
1 post MDS. Median age was 56 (42.7-65.5). Disease status
prior to transplant per DIPSS was: intermediate-1 (4), inter-
mediate-2 (6), and high-risk (2). Splenectomy prior to
transplant was performed in 8 patients. JAK2 V617Fmutation
status was known on ﬁve patients and was detected on 3.
Five pts received a TCD marrow graft and were conditioned
with a TBI-based regimen and 7 pts received TCD peripheral
blood graft and were conditioned with a chemotherapy
